Lixisenatide

GLP-1 Receptor Agonist

Also sold as Adlyxin, Lyxumia.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Lixisenatide has no classical depletion machinery. It is a 44-amino-acid peptide cleared by glomerular filtration and general proteolysis, not by hepatic CYP450 metabolism; it induces or inhibits no drug-metabolizing enzyme; it is not orally dosed, so it cannot chelate dietary minerals in the gut. The one mechanism it plainly does have, stated in its own FDA label, is delayed gastric emptying, which slows absorption of co-administered oral drugs and, through nausea, vomiting, and reduced food intake, can plausibly reduce intake of any nutrient. That single mechanism is the root of every classical-nutrient entry below.

GLP-1 receptor agonist · ATC A10BJ03 · also sold as Adlyxin and Lyxumia and Soliqua (combo w/ insulin glargine) · reviewed 2026-09-20. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Lixisenatide in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe: severe: ≥2 independent Tier A sources with this drug in the cohort, direct measurement, consistent direction, clinically meaningful magnitude, named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate: moderate: ≥1 Tier A source with this drug in the cohort showing a real but bounded deficit (exposure window, subgroup, low frequency, or functional-only).
Yellow — Low: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where a class member has real data but this drug does not; also context flags and reverse-direction/protective findings.
Not graded — disclosed evidence gap: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: evidence gap: no Tier B/C evidence exists to support even yellow, AND no circulating claim exists to rebut as white. A genuine literature gap, not a safety finding.

What the research found

Fluid and electrolyte status

Orange — Moderate

See study details

In patients who develop substantial nausea, vomiting, or diarrhea on lixisenatide, GI fluid losses have been linked in postmarketing reports to volume depletion and acute kidney injury; this is a retention/depletion risk tied to a defined at-risk subgroup, not a routine effect in most users.

Full detail and limits

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real but bounded deficit (exposure window, subgroup, low frequency, or functional-only). Orange

Limits on what this shows

Key negative findings: The large ELIXA cardiovascular outcomes trial (n=6068, type 2 diabetes with recent acute coronary syndrome) did not report an excess signal of renal failure driving trial discontinuation in the lixisenatide arm versus placebo at the population level; the AKI signal is a postmarketing case-level finding in a bounded subgroup, not a trial-wide effect.
At-risk subgroups: Pre-existing renal impairment (exposure already rises 34-124% with mild-to-severe renal dysfunction), older adults, patients on diuretics or other nephrotoxic/volume-sensitive drugs, and anyone with poorly tolerated GI adverse effects.
Counter-evidence: Most patients on lixisenatide do not develop clinically significant dehydration; GI adverse effects are typically mild-to-moderate and improve over the first weeks of treatment per the label's tolerability data.

Regulatory status

FDA label carries a specific warning: "There have been postmarketing reports of acute kidney injury...in patients who experienced gastrointestinal reactions leading to dehydration."

Population evidence

Postmarketing pharmacovigilance case reports plus the label's own clinical-trial GI adverse-event rates: any GI adverse reaction 39.7%, nausea ~25%, vomiting ~10% of lixisenatide-treated patients across the pivotal program.

Mechanism

Named: GLP-1-receptor-mediated delay in gastric emptying provokes nausea/vomiting in a subset of patients; sustained vomiting or diarrhea causes GI fluid and electrolyte (sodium, potassium) loss and volume contraction, which can precipitate prerenal azotemia/AKI, especially with background renal impairment.

Counter-evidence held on record

This is a volume-depletion and electrolyte-loss risk driven by vomiting/diarrhea, not a dietary mineral deficiency. The remedy is monitoring and rehydration guidance during GI illness, not routine electrolyte supplementation. Empiric potassium or sodium supplementation without measured levels would risk overcorrection, particularly given lixisenatide's own renal-impairment exposure warning.

Vitamin B12

Yellow — Low

See study details

GLP-1 receptor agonists as a class are associated with reduced B12 status through appetite suppression and reduced food intake; lixisenatide shares the mechanism but was not itself in the studied cohorts and produces a substantially smaller weight-loss/appetite effect than the agents actually studied.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where a class member has real data but this drug does not; also context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

Key negative/null findings: No study measuring serum B12 in lixisenatide-treated patients specifically was located in PubMed, Europe PMC, or Crossref searches across multiple phrasings.
At-risk subgroups: Patients co-prescribed metformin (which does have a documented B12-absorption mechanism), older adults, and anyone with substantial appetite suppression or weight loss on therapy.
Counter-evidence: Lixisenatide's own pivotal trials (GetGoal program) show placebo-subtracted weight loss on the order of 2-3 kg, markedly smaller than semaglutide or tirzepatide trials, making a B12-relevant reduction in food intake mechanistically weaker for this specific drug than for the agents actually studied.

Regulatory status

Not listed as a monitoring requirement in the Adlyxin label.

Population evidence

A 2026 narrative review, "Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy" (Clinical Obesity), and a related 2026 mechanistic review name B12 as one of the "most consistent signals," but the drugs actually carrying that evidence are liraglutide, semaglutide, and tirzepatide; lixisenatide is not named in either review.

Mechanism

Named, class-level, and plausible for lixisenatide: GLP-1 receptor agonism delays gastric emptying and suppresses appetite, reducing intake of B12-containing foods (Mechanism H). No absorption-blocking or intrinsic-factor mechanism (unlike metformin) has been identified for any GLP-1 agonist including lixisenatide.

Counter-evidence held on record

This is class extrapolation, not a lixisenatide-confirmed finding. Do not present as an established lixisenatide effect on the consumer surface; frame as a monitoring prompt only, distinct from metformin's separately-documented B12 mechanism when the two are co-prescribed.

Vitamin D

Yellow — Low

See study details

Vitamin D is named among the "consistent signals" in GLP-1 micronutrient reviews built on newer, more potent class members; the intake-reduction mechanism is plausible but unconfirmed for lixisenatide itself.

Full detail and limits

Limits on what this shows

Key negative/null findings: None located specific to lixisenatide; no measured serum 25-OH-D data for this drug found.
At-risk subgroups: Patients with limited sun exposure or pre-existing low intake, and those experiencing substantial weight loss with reduced overall food variety.
Counter-evidence: No trial-level signal in lixisenatide's own program (ELIXA, GetGoal series) was identified addressing vitamin D status; lixisenatide's modest weight-loss effect limits how strongly the intake mechanism would be expected to operate.

Regulatory status

Not addressed in the Adlyxin label.

Population evidence

Dietary-intake and administrative-dataset evidence in the 2026 GLP-1 micronutrient reviews (liraglutide, semaglutide, tirzepatide cohorts); no lixisenatide-specific vitamin D study identified.

Mechanism

Named, class-level: reduced overall caloric and dietary variety from appetite suppression can reduce intake of vitamin D-containing/fortified foods (Mechanism H). This is distinct from, and should not be conflated with, weight-loss-associated bone remodeling (see Fails verification).

Counter-evidence held on record

Class extrapolation only. Never present alongside bone-density claims as if vitamin D deficiency were the cause of GLP-1-associated bone loss; that is a separate, unconfirmed causal chain (see Fails verification).

Thiamine

Yellow — Low

See study details

Wernicke encephalopathy has been reported with GLP-1 agonists as a class, but a dedicated 2026 pharmacovigilance study that monitored lixisenatide specifically attributed zero of 15 cases to it.

Full detail and limits

Limits on what this shows

Key negative/null findings: Zero of 15 pharmacovigilance-reported WE cases were attributed to lixisenatide despite it being monitored in the same database and having been marketed since 2016 (longer market exposure than tirzepatide), consistent with its markedly smaller weight-loss/vomiting-severity profile.
At-risk subgroups: Patients with prolonged, severe vomiting or very low caloric intake on any GLP-1 agonist, alcohol use disorder, or pre-existing malnutrition.
Counter-evidence: The null case count for lixisenatide specifically, in the same surveillance system that flagged 14 cases for the two higher-potency agents, is itself meaningful counter-evidence against a lixisenatide-specific thiamine risk of the same magnitude as the newer drugs.

Regulatory status

Not addressed in the Adlyxin label.

Population evidence

"Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review" (2026) mined the FDA Adverse Event Reporting System (FAERS) across six GLP-1 drugs (dulaglutide, tirzepatide, semaglutide, exenatide, liraglutide, lixisenatide) and found 15 total WE cases: 8 attributed to semaglutide, 6 to tirzepatide, and none of the 15 attributed to lixisenatide.

Mechanism

Named, class-level: rapid weight loss with prolonged vomiting/severely reduced caloric intake can precipitate thiamine depletion and Wernicke encephalopathy (a recognized mechanism from bariatric surgery and hyperemesis literature); plausible in principle for any GLP-1 agonist causing comparable intake reduction.

Counter-evidence held on record

Grade this as a theoretical, class-level mechanism with reassuring lixisenatide-specific pharmacovigilance data, not as an active lixisenatide safety signal. Any consumer-facing prompt should note the drug-specific null finding rather than the class headline alone.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

See study details

In one in vitro study, lixisenatide increased markers of mitochondrial biogenesis rather than impairing them; this is a protective, not a depleting, signal, and has not been tested in vivo or in diabetic patients.

Full detail and limits

Limits on what this shows

Key negative/null findings: Single in vitro cell-line study; no animal or human confirmation identified. Endothelial cells are not the primary tissue of concern for a systemic "mitochondrial burden" claim in patients.
At-risk subgroups: Not applicable — this is a protective, not a depleting, finding.
Counter-evidence: No study was found showing lixisenatide impairing mitochondrial structure or function in any tissue.

Regulatory status

Not addressed in the Adlyxin label.

Population evidence

Zhao Z, Pu Y. "Lixisenatide enhances mitochondrial biogenesis and function through regulating the CREB/PGC-1α pathway." Biochem Biophys Res Commun. 2019;508(4):1120-1125. In vitro study in human umbilical vein endothelial cells (HUVECs), lixisenatide 5-20 nM for 24-48 hours.

Mechanism

Named: lixisenatide increased PGC-1α expression (the "master regulator" of mitochondrial biogenesis), promoted downstream NRF1/TFAM expression, raised mitochondrial-to-nuclear DNA ratio, mitochondrial mass, and citrate synthase activity, via CREB phosphorylation (blocked by the CREB inhibitor H89).

Counter-evidence held on record

Reverse-direction finding: this evidence runs opposite to a depletion narrative. It must never be presented to consumers as a reason lixisenatide "burdens" mitochondria; if surfaced at all, it should be framed as a preliminary protective signal requiring in vivo confirmation, not as a monitoring prompt for supplementation.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

See study details

In one diabetic-rat cerebral ischemia/reperfusion model, lixisenatide was protective rather than harmful; a related in vitro "protective" oxidative-stress paper on lixisenatide was retracted in 2021 and is excluded from this grade.

Full detail, limits and 1 references

Limits on what this shows

Key negative/null findings: A separate 2019 paper reporting lixisenatide protection against "high free fatty acid-induced oxidative stress" (Artificial Cells, Nanomedicine, and Biotechnology, DOI 10.1080/21691401.2019.1620248) was formally retracted on 2021-08-10 and is excluded from evidence here; see Fails verification.
At-risk subgroups: Not applicable — this is a protective, not a depleting, finding, and is animal-only.
Counter-evidence: No study was found showing lixisenatide increasing systemic oxidative stress markers in humans or animals.

Regulatory status

Not addressed in the Adlyxin label.

Population evidence

Abdel-latif RG, Heeba GH, Taye A, Khalifa MMA. "Lixisenatide, a novel GLP-1 analog, protects against cerebral ischemia/reperfusion injury in diabetic rats." Naunyn Schmiedebergs Arch Pharmacol. 2018. Animal (rat) model, diabetic cerebral ischemia/reperfusion.

Mechanism

Named at the class level: GLP-1 receptor agonism is reported to reduce oxidative and inflammatory injury in ischemia-reperfusion models; specific oxidative marker values from this paper were not independently verified during this review (see access note in Sources).

Counter-evidence held on record

Reverse-direction, animal-only finding. Do not present as a reason to add antioxidant supplementation; if surfaced, frame strictly as preliminary and note the retracted companion paper explicitly so readers are not misled by residual citations of it elsewhere.

Zhao Q, Xu H, Zhang L, Liu L, Wang L. GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response. Artificial Cells, Nanomedicine, and Biotechnology. 2019. — RETRACTED 2021-08-10. DOI 10.1080/21691401.2019.1620248. PMID 31174433. Not used as supporting evidence anywhere in this dossier; listed here to document that it was found, checked, and excluded, and to prevent its reuse elsewhere.Retracted article — excluded from all grading.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Iron

Yellow — Low

See study details

Iron is named as one of the "strongest" GLP-1 micronutrient signals in 2026 reviews, but those reviews are built on liraglutide, semaglutide, and tirzepatide data; lixisenatide does not appear in the cited cohorts and has no dedicated iron/anemia study of its own.

Full detail and limits

Limits on what this shows

Key negative/null findings: No hemoglobin, ferritin, or transferrin saturation data for lixisenatide-treated patients were located in PubMed, Europe PMC, or Crossref searches.
At-risk subgroups: Menstruating individuals, patients with reduced dietary variety after starting therapy, and those with baseline low iron stores.
Counter-evidence: None specific to lixisenatide found; the class-level anemia discussion in consumer/medical press (e.g. Medscape coverage) centers explicitly on tirzepatide and semaglutide, not lixisenatide.

Regulatory status

Anemia/iron status is not addressed in the Adlyxin label.

Population evidence

Mechanistic absorption studies, observational cohorts, and pharmacovigilance signals cited in the 2026 "Micronutrient risk with GLP-1 receptor and dual incretin agonists" review, none including lixisenatide.

Mechanism

Named, class-level: reduced dietary intake of iron-rich foods from appetite suppression (Mechanism H); delayed gastric emptying could theoretically alter gastric-acid-dependent nonheme iron solubilization, though this is not demonstrated for lixisenatide specifically.

Counter-evidence held on record

Class extrapolation only; do not present as lixisenatide-confirmed. See also the Oxygen delivery/utilization entry below, which extends from this same mechanism and should not be counted as independent confirmation (see Overlap map).

Copper

Not graded — disclosed evidence gap

See study details

No evidence at any tier, and no circulating consumer claim, was found linking lixisenatide (or GLP-1 receptor agonists generally) to copper status.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Both conditions for ungraded are met: (1) no Tier B or Tier C evidence exists, drug-specific or class-level, supporting even a yellow grade for copper and GLP-1 agonists; the 2026 GLP-1 micronutrient risk review that lists 14 other nutrients (iron, B12, thiamine, folate, vitamin D, vitamin A, vitamins E and K, calcium, magnesium, phosphate, zinc, selenium, iodine, potassium) does not include copper at all. (2) No circulating consumer claim about lixisenatide/GLP-1 drugs and copper was found in searches of general and consumer-health sources.

Search channels tried

WebSearch (multiple phrasings including "lixisenatide copper"), Europe PMC REST API, Crossref API, DailyMed/FDA label. No tooling block encountered for this specific query; the absence reflects a genuine literature gap at this time, not an access failure.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Yellow — Low

See study details

Other GLP-1 agonists (chiefly liraglutide) have documented gut microbiome effects in animal models, and a mechanistic link (altered gastric emptying and GI transit) is plausible for lixisenatide, but no lixisenatide-specific microbiome study was found in a dedicated title-level search.

Full detail and limits

Limits on what this shows

Key negative/null findings: None found specific to lixisenatide; absence of any title-level hit after a dedicated multi-database search (PubMed, Europe PMC) is itself notable and disclosed here rather than silently omitted.
At-risk subgroups: Cannot be specified without drug-specific data.
Counter-evidence: None identified either way for lixisenatide specifically.

Regulatory status

Not addressed in the Adlyxin label.

Population evidence

Liraglutide has been shown to alter gut microbiota composition in high-fat-diet rodent models (multiple independent studies); a 2026 narrative review and a 2026 "bidirectional relationship" review discuss GLP-1 agonists and the microbiome generally. A dedicated Europe PMC title search for "lixisenatide AND (microbiome OR microbiota OR gut flora)" returned zero results.

Mechanism

Named, class-level: delayed gastric emptying and altered GI transit time can shift luminal pH, nutrient delivery timing, and bile acid dynamics, all of which influence microbial composition (Mechanism A/G). Plausible for lixisenatide given its confirmed gastric-emptying effect, but unconfirmed.

Counter-evidence held on record

Pure class extrapolation from a different molecule (liraglutide) in animal models; do not present as lixisenatide-confirmed microbiome disruption.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production

Yellow — Low

See study details

The same in vitro HUVEC study that found increased mitochondrial biogenesis also reported increased mitochondrial respiration rate and ATP generation with lixisenatide, not a deficit.

Full detail and limits

Limits on what this shows

Key negative/null findings: Single in vitro study; no in vivo or human ATP/energy-metabolism data for lixisenatide identified.
At-risk subgroups: Not applicable — protective finding, not a depleting one.
Counter-evidence: No study was found showing lixisenatide reducing ATP output in any tissue or model.

Regulatory status

Not addressed in the Adlyxin label.

Population evidence

Zhao Z, Pu Y. Biochem Biophys Res Commun. 2019;508(4):1120-1125 (see Mitochondrial burden entry). Same in vitro HUVEC model, lixisenatide 5-20 nM.

Mechanism

Named: CREB/PGC-1α-driven mitochondrial biogenesis was reported to increase mitochondrial respiration rate and cellular ATP generation.

Counter-evidence held on record

This entry rests on the same source and experiment as Mitochondrial burden above (see Overlap map) and must not be counted as a second, independent line of evidence. Reverse-direction: not a basis for any "low energy" supplementation prompt.

Oxygen delivery/utilization

Yellow — Low

See study details

No lixisenatide-specific hemoglobin, hematocrit, or oxygen-delivery data were found; a theoretical link exists only insofar as reduced iron intake (see Iron entry) could, if severe and sustained, contribute to iron-deficiency anemia.

Full detail and limits

Limits on what this shows

Key negative/null findings: None found specific to lixisenatide.
At-risk subgroups: Same as the Iron entry: cannot be specified without drug-specific data.
Counter-evidence: None identified either way for lixisenatide.

Regulatory status

Not addressed in the Adlyxin label; no hemoglobin/hematocrit monitoring requirement.

Population evidence

Class-level consumer-medical coverage of GLP-1-associated anemia concerns (e.g. Medscape, 2025) centers explicitly on tirzepatide; no lixisenatide-specific hemoglobin/hematocrit study identified in PubMed or Europe PMC searches.

Mechanism

Theoretical only, and entirely downstream of the Iron entry's reduced-intake mechanism above; no separate mechanism specific to oxygen delivery was identified.

Counter-evidence held on record

This entry shares its entire evidence basis with the Iron entry above (see Overlap map) and adds no independent confirmation. Do not present the two together as if they were separate lines of evidence.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

GLP-1 drugs (including lixisenatide) "deplete" calcium/vitamin D, causing bone loss
Where it comes from: General GLP-1/weight-loss consumer commentary linking rapid weight loss to osteoporosis risk; echoed in reviews such as "Weight loss induced bone loss: mechanism of action and clinical implications" (2025).
Why it fails: Bone mineral density changes with GLP-1 therapy are attributed in the literature to weight-loss-associated bone remodeling (reduced mechanical loading, changes in fat-derived hormones), not to a measured drop in serum calcium or vitamin D caused by the drug. Fracture/BMD is a clinical outcome, not a nutrient-deficiency finding, per Hard Rule 2. No study measuring serum calcium or 25-OH-vitamin D specifically in lixisenatide-treated patients was found to support a direct depletion claim.
Lixisenatide causes B12 deficiency through the same absorption-blocking mechanism as metformin
Where it comes from: Common conflation in consumer GLP-1/metformin combination-therapy content, since the two drugs are frequently co-prescribed in type 2 diabetes.
Why it fails: Metformin's B12 mechanism is a documented calcium-dependent interference with the cubilin/intrinsic-factor absorption complex in the terminal ileum. No such absorption-interference mechanism has been identified for lixisenatide or any GLP-1 receptor agonist; the only plausible GLP-1-class mechanism is reduced dietary intake (see the Vitamin B12 yellow entry), which is mechanistically distinct and should not be described using metformin's absorption-blockade language.
Lixisenatide directly increases systemic oxidative stress / damages mitochondria
Where it comes from: Generic "drug burden" framing sometimes applied indiscriminately across diabetes drug classes in consumer nutrient-depletion content.
Why it fails: Contradicted by this drug's own available data: the two lixisenatide-specific studies located (HUVEC mitochondrial biogenesis study and diabetic-rat cerebral ischemia study) both found protective, not harmful, effects on mitochondrial and oxidative markers. A third paper claiming a protective oxidative-stress effect was formally retracted in 2021 (DOI 10.1080/21691401.2019.1620248) and supports neither direction; it is excluded from evidence entirely and cited here only to prevent it from being mistakenly used elsewhere.

All references used above

Lixisenatide

Findings for this medication

What the research found

Fluid and electrolyte status

Vitamin B12

Vitamin D

Thiamine

The five body-system areas

⚡Mitochondrial Burden

Mitochondrial burden

💥Oxidative Stress

Oxidative stress

⚖️Copper and Iron Balance

Iron

Copper

🌿Gut Microbiome Risk

Gut microbiome risk

💨Oxygen and ATP Output

ATP production

Oxygen delivery/utilization

Claims checked and not supported

GLP-1 drugs (including lixisenatide) "deplete" calcium/vitamin D, causing bone loss

Lixisenatide causes B12 deficiency through the same absorption-blocking mechanism as metformin

Lixisenatide directly increases systemic oxidative stress / damages mitochondria

Mitochondrial Burden

Oxidative Stress

Copper and Iron Balance

Gut Microbiome Risk

Oxygen and ATP Output